nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—CYP3A7—Sorafenib—thyroid cancer	0.108	0.202	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.108	0.202	CbGbCtD
Zalcitabine—CYP3A5—Sorafenib—thyroid cancer	0.0807	0.152	CbGbCtD
Zalcitabine—CYP2C9—Sorafenib—thyroid cancer	0.0541	0.102	CbGbCtD
Zalcitabine—CYP3A4—Vandetanib—thyroid cancer	0.0522	0.0981	CbGbCtD
Zalcitabine—CYP2D6—Sorafenib—thyroid cancer	0.0495	0.093	CbGbCtD
Zalcitabine—CYP3A4—Sorafenib—thyroid cancer	0.0315	0.0591	CbGbCtD
Zalcitabine—CYP2D6—Doxorubicin—thyroid cancer	0.03	0.0564	CbGbCtD
Zalcitabine—CYP3A4—Doxorubicin—thyroid cancer	0.0191	0.0359	CbGbCtD
Zalcitabine—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.00331	0.519	CbGdCrCtD
Zalcitabine—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.00306	0.481	CbGdCrCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00177	0.144	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.000682	0.0552	CbGpPWpGaD
Zalcitabine—Candida infection—Doxorubicin—thyroid cancer	0.000608	0.00135	CcSEcCtD
Zalcitabine—Skin exfoliation—Doxorubicin—thyroid cancer	0.000608	0.00135	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000605	0.00135	CcSEcCtD
Zalcitabine—Hypertonia—Epirubicin—thyroid cancer	0.000603	0.00134	CcSEcCtD
Zalcitabine—Vaginal infection—Doxorubicin—thyroid cancer	0.000601	0.00134	CcSEcCtD
Zalcitabine—Blood urea increased—Doxorubicin—thyroid cancer	0.000601	0.00134	CcSEcCtD
Zalcitabine—Abnormal vision—Epirubicin—thyroid cancer	0.0006	0.00134	CcSEcCtD
Zalcitabine—Mental disability—Epirubicin—thyroid cancer	0.000597	0.00133	CcSEcCtD
Zalcitabine—Dyspnoea—Sorafenib—thyroid cancer	0.000592	0.00132	CcSEcCtD
Zalcitabine—Dry eye—Doxorubicin—thyroid cancer	0.000588	0.00131	CcSEcCtD
Zalcitabine—Lymphadenopathy—Epirubicin—thyroid cancer	0.000585	0.0013	CcSEcCtD
Zalcitabine—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000585	0.0013	CcSEcCtD
Zalcitabine—Dyspepsia—Sorafenib—thyroid cancer	0.000585	0.0013	CcSEcCtD
Zalcitabine—Oesophagitis—Doxorubicin—thyroid cancer	0.000582	0.0013	CcSEcCtD
Zalcitabine—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000579	0.00129	CcSEcCtD
Zalcitabine—Decreased appetite—Sorafenib—thyroid cancer	0.000577	0.00129	CcSEcCtD
Zalcitabine—Bladder pain—Doxorubicin—thyroid cancer	0.000576	0.00128	CcSEcCtD
Zalcitabine—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000574	0.00128	CcSEcCtD
Zalcitabine—Diabetes mellitus—Epirubicin—thyroid cancer	0.000574	0.00128	CcSEcCtD
Zalcitabine—Fatigue—Sorafenib—thyroid cancer	0.000573	0.00127	CcSEcCtD
Zalcitabine—Pain—Sorafenib—thyroid cancer	0.000568	0.00126	CcSEcCtD
Zalcitabine—Vascular purpura—Epirubicin—thyroid cancer	0.000558	0.00124	CcSEcCtD
Zalcitabine—Hypertonia—Doxorubicin—thyroid cancer	0.000558	0.00124	CcSEcCtD
Zalcitabine—Abnormal vision—Doxorubicin—thyroid cancer	0.000555	0.00124	CcSEcCtD
Zalcitabine—Eye pain—Epirubicin—thyroid cancer	0.000553	0.00123	CcSEcCtD
Zalcitabine—Mental disability—Doxorubicin—thyroid cancer	0.000552	0.00123	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000543	0.00121	CcSEcCtD
Zalcitabine—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000542	0.00121	CcSEcCtD
Zalcitabine—Renal failure acute—Epirubicin—thyroid cancer	0.000541	0.0012	CcSEcCtD
Zalcitabine—Hot flush—Epirubicin—thyroid cancer	0.000534	0.00119	CcSEcCtD
Zalcitabine—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000531	0.00118	CcSEcCtD
Zalcitabine—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000531	0.00118	CcSEcCtD
Zalcitabine—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000529	0.00118	CcSEcCtD
Zalcitabine—Menopausal symptoms—Epirubicin—thyroid cancer	0.000529	0.00118	CcSEcCtD
Zalcitabine—Urticaria—Sorafenib—thyroid cancer	0.000528	0.00117	CcSEcCtD
Zalcitabine—Abdominal pain—Sorafenib—thyroid cancer	0.000525	0.00117	CcSEcCtD
Zalcitabine—Body temperature increased—Sorafenib—thyroid cancer	0.000525	0.00117	CcSEcCtD
Zalcitabine—Renal impairment—Epirubicin—thyroid cancer	0.000525	0.00117	CcSEcCtD
Zalcitabine—Dermatitis bullous—Epirubicin—thyroid cancer	0.000523	0.00116	CcSEcCtD
Zalcitabine—Purpura—Epirubicin—thyroid cancer	0.000518	0.00115	CcSEcCtD
Zalcitabine—Vascular purpura—Doxorubicin—thyroid cancer	0.000517	0.00115	CcSEcCtD
Zalcitabine—Eye pain—Doxorubicin—thyroid cancer	0.000512	0.00114	CcSEcCtD
Zalcitabine—Cardiac failure—Epirubicin—thyroid cancer	0.000512	0.00114	CcSEcCtD
Zalcitabine—Hypoglycaemia—Epirubicin—thyroid cancer	0.000512	0.00114	CcSEcCtD
Zalcitabine—Hyponatraemia—Epirubicin—thyroid cancer	0.000501	0.00112	CcSEcCtD
Zalcitabine—Renal failure acute—Doxorubicin—thyroid cancer	0.0005	0.00111	CcSEcCtD
Zalcitabine—Pain in extremity—Epirubicin—thyroid cancer	0.000499	0.00111	CcSEcCtD
Zalcitabine—Osteoarthritis—Epirubicin—thyroid cancer	0.000499	0.00111	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000499	0.00111	CcSEcCtD
Zalcitabine—Hot flush—Doxorubicin—thyroid cancer	0.000494	0.0011	CcSEcCtD
Zalcitabine—Migraine—Epirubicin—thyroid cancer	0.000492	0.00109	CcSEcCtD
Zalcitabine—Affect lability—Epirubicin—thyroid cancer	0.000492	0.00109	CcSEcCtD
Zalcitabine—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00049	0.00109	CcSEcCtD
Zalcitabine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00049	0.00109	CcSEcCtD
Zalcitabine—Hypersensitivity—Sorafenib—thyroid cancer	0.000489	0.00109	CcSEcCtD
Zalcitabine—Renal impairment—Doxorubicin—thyroid cancer	0.000486	0.00108	CcSEcCtD
Zalcitabine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000483	0.00108	CcSEcCtD
Zalcitabine—Purpura—Doxorubicin—thyroid cancer	0.000479	0.00107	CcSEcCtD
Zalcitabine—Asthenia—Sorafenib—thyroid cancer	0.000477	0.00106	CcSEcCtD
Zalcitabine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000473	0.00105	CcSEcCtD
Zalcitabine—Cardiac failure—Doxorubicin—thyroid cancer	0.000473	0.00105	CcSEcCtD
Zalcitabine—Mood swings—Epirubicin—thyroid cancer	0.000473	0.00105	CcSEcCtD
Zalcitabine—Pruritus—Sorafenib—thyroid cancer	0.00047	0.00105	CcSEcCtD
Zalcitabine—Ataxia—Epirubicin—thyroid cancer	0.00047	0.00105	CcSEcCtD
Zalcitabine—Blood creatinine increased—Epirubicin—thyroid cancer	0.000468	0.00104	CcSEcCtD
Zalcitabine—Hyponatraemia—Doxorubicin—thyroid cancer	0.000464	0.00103	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000462	0.00103	CcSEcCtD
Zalcitabine—Osteoarthritis—Doxorubicin—thyroid cancer	0.000462	0.00103	CcSEcCtD
Zalcitabine—Pain in extremity—Doxorubicin—thyroid cancer	0.000462	0.00103	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—CHST14—thyroid cancer	0.000459	0.0371	CbGpPWpGaD
Zalcitabine—Dry skin—Epirubicin—thyroid cancer	0.000458	0.00102	CcSEcCtD
Zalcitabine—Abdominal pain upper—Epirubicin—thyroid cancer	0.000456	0.00102	CcSEcCtD
Zalcitabine—Affect lability—Doxorubicin—thyroid cancer	0.000455	0.00101	CcSEcCtD
Zalcitabine—Migraine—Doxorubicin—thyroid cancer	0.000455	0.00101	CcSEcCtD
Zalcitabine—Hypokalaemia—Epirubicin—thyroid cancer	0.000454	0.00101	CcSEcCtD
Zalcitabine—Diarrhoea—Sorafenib—thyroid cancer	0.000454	0.00101	CcSEcCtD
Zalcitabine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000447	0.000994	CcSEcCtD
Zalcitabine—Gastritis—Epirubicin—thyroid cancer	0.000442	0.000984	CcSEcCtD
Zalcitabine—Muscular weakness—Epirubicin—thyroid cancer	0.00044	0.000981	CcSEcCtD
Zalcitabine—Dizziness—Sorafenib—thyroid cancer	0.000439	0.000978	CcSEcCtD
Zalcitabine—Mood swings—Doxorubicin—thyroid cancer	0.000438	0.000975	CcSEcCtD
Zalcitabine—Abdominal distension—Epirubicin—thyroid cancer	0.000435	0.000967	CcSEcCtD
Zalcitabine—Ataxia—Doxorubicin—thyroid cancer	0.000434	0.000967	CcSEcCtD
Zalcitabine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000433	0.000964	CcSEcCtD
Zalcitabine—Dysphagia—Epirubicin—thyroid cancer	0.000432	0.000961	CcSEcCtD
Zalcitabine—Eosinophilia—Epirubicin—thyroid cancer	0.000427	0.000951	CcSEcCtD
Zalcitabine—Dry skin—Doxorubicin—thyroid cancer	0.000424	0.000943	CcSEcCtD
Zalcitabine—Pancreatitis—Epirubicin—thyroid cancer	0.000423	0.000942	CcSEcCtD
Zalcitabine—Vomiting—Sorafenib—thyroid cancer	0.000422	0.00094	CcSEcCtD
Zalcitabine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000422	0.00094	CcSEcCtD
Zalcitabine—Hypokalaemia—Doxorubicin—thyroid cancer	0.000421	0.000936	CcSEcCtD
Zalcitabine—Rash—Sorafenib—thyroid cancer	0.000419	0.000932	CcSEcCtD
Zalcitabine—Dermatitis—Sorafenib—thyroid cancer	0.000418	0.000931	CcSEcCtD
Zalcitabine—Headache—Sorafenib—thyroid cancer	0.000416	0.000926	CcSEcCtD
Zalcitabine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000413	0.00092	CcSEcCtD
Zalcitabine—Gastritis—Doxorubicin—thyroid cancer	0.000409	0.00091	CcSEcCtD
Zalcitabine—Muscular weakness—Doxorubicin—thyroid cancer	0.000408	0.000907	CcSEcCtD
Zalcitabine—Dysuria—Epirubicin—thyroid cancer	0.000404	0.000899	CcSEcCtD
Zalcitabine—Neutropenia—Epirubicin—thyroid cancer	0.000404	0.000899	CcSEcCtD
Zalcitabine—Abdominal distension—Doxorubicin—thyroid cancer	0.000402	0.000895	CcSEcCtD
Zalcitabine—Dysphagia—Doxorubicin—thyroid cancer	0.000399	0.000889	CcSEcCtD
Zalcitabine—Pollakiuria—Epirubicin—thyroid cancer	0.000399	0.000888	CcSEcCtD
Zalcitabine—Eosinophilia—Doxorubicin—thyroid cancer	0.000395	0.00088	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000394	0.000877	CcSEcCtD
Zalcitabine—Pancreatitis—Doxorubicin—thyroid cancer	0.000392	0.000872	CcSEcCtD
Zalcitabine—Weight decreased—Epirubicin—thyroid cancer	0.00039	0.000869	CcSEcCtD
Zalcitabine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000389	0.000867	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.000388	0.0314	CbGpPWpGaD
Zalcitabine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000377	0.00084	CcSEcCtD
Zalcitabine—Jaundice—Epirubicin—thyroid cancer	0.000375	0.000835	CcSEcCtD
Zalcitabine—Neutropenia—Doxorubicin—thyroid cancer	0.000373	0.000831	CcSEcCtD
Zalcitabine—Dysuria—Doxorubicin—thyroid cancer	0.000373	0.000831	CcSEcCtD
Zalcitabine—Pollakiuria—Doxorubicin—thyroid cancer	0.000369	0.000821	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000365	0.000812	CcSEcCtD
Zalcitabine—Epistaxis—Epirubicin—thyroid cancer	0.000363	0.000808	CcSEcCtD
Zalcitabine—Weight decreased—Doxorubicin—thyroid cancer	0.000361	0.000804	CcSEcCtD
Zalcitabine—Sinusitis—Epirubicin—thyroid cancer	0.000361	0.000804	CcSEcCtD
Zalcitabine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00036	0.000802	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000349	0.000777	CcSEcCtD
Zalcitabine—Jaundice—Doxorubicin—thyroid cancer	0.000347	0.000773	CcSEcCtD
Zalcitabine—Rhinitis—Epirubicin—thyroid cancer	0.000346	0.000771	CcSEcCtD
Zalcitabine—Hepatitis—Epirubicin—thyroid cancer	0.000345	0.000769	CcSEcCtD
Zalcitabine—Pharyngitis—Epirubicin—thyroid cancer	0.000343	0.000763	CcSEcCtD
Zalcitabine—Epistaxis—Doxorubicin—thyroid cancer	0.000336	0.000748	CcSEcCtD
Zalcitabine—Sinusitis—Doxorubicin—thyroid cancer	0.000334	0.000744	CcSEcCtD
Zalcitabine—Visual impairment—Epirubicin—thyroid cancer	0.000333	0.000741	CcSEcCtD
Zalcitabine—Eye disorder—Epirubicin—thyroid cancer	0.000323	0.000719	CcSEcCtD
Zalcitabine—Tinnitus—Epirubicin—thyroid cancer	0.000322	0.000717	CcSEcCtD
Zalcitabine—Flushing—Epirubicin—thyroid cancer	0.000321	0.000714	CcSEcCtD
Zalcitabine—Rhinitis—Doxorubicin—thyroid cancer	0.00032	0.000714	CcSEcCtD
Zalcitabine—Hepatitis—Doxorubicin—thyroid cancer	0.00032	0.000712	CcSEcCtD
Zalcitabine—Pharyngitis—Doxorubicin—thyroid cancer	0.000317	0.000706	CcSEcCtD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000314	0.0254	CbGpPWpGaD
Zalcitabine—Chills—Epirubicin—thyroid cancer	0.00031	0.00069	CcSEcCtD
Zalcitabine—Arrhythmia—Epirubicin—thyroid cancer	0.000309	0.000687	CcSEcCtD
Zalcitabine—Visual impairment—Doxorubicin—thyroid cancer	0.000308	0.000686	CcSEcCtD
Zalcitabine—Alopecia—Epirubicin—thyroid cancer	0.000305	0.00068	CcSEcCtD
Zalcitabine—Eye disorder—Doxorubicin—thyroid cancer	0.000299	0.000665	CcSEcCtD
Zalcitabine—Tinnitus—Doxorubicin—thyroid cancer	0.000298	0.000664	CcSEcCtD
Zalcitabine—Flushing—Doxorubicin—thyroid cancer	0.000297	0.000661	CcSEcCtD
Zalcitabine—Flatulence—Epirubicin—thyroid cancer	0.000296	0.00066	CcSEcCtD
Zalcitabine—Tension—Epirubicin—thyroid cancer	0.000295	0.000657	CcSEcCtD
Zalcitabine—Dysgeusia—Epirubicin—thyroid cancer	0.000295	0.000656	CcSEcCtD
Zalcitabine—Nervousness—Epirubicin—thyroid cancer	0.000292	0.00065	CcSEcCtD
Zalcitabine—Back pain—Epirubicin—thyroid cancer	0.000291	0.000648	CcSEcCtD
Zalcitabine—Muscle spasms—Epirubicin—thyroid cancer	0.000289	0.000644	CcSEcCtD
Zalcitabine—Chills—Doxorubicin—thyroid cancer	0.000287	0.000639	CcSEcCtD
Zalcitabine—Arrhythmia—Doxorubicin—thyroid cancer	0.000286	0.000636	CcSEcCtD
Zalcitabine—Vision blurred—Epirubicin—thyroid cancer	0.000283	0.000631	CcSEcCtD
Zalcitabine—Alopecia—Doxorubicin—thyroid cancer	0.000282	0.000629	CcSEcCtD
Zalcitabine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000279	0.000621	CcSEcCtD
Zalcitabine—Anaemia—Epirubicin—thyroid cancer	0.000278	0.000619	CcSEcCtD
Zalcitabine—Agitation—Epirubicin—thyroid cancer	0.000276	0.000615	CcSEcCtD
Zalcitabine—Flatulence—Doxorubicin—thyroid cancer	0.000274	0.000611	CcSEcCtD
Zalcitabine—Tension—Doxorubicin—thyroid cancer	0.000273	0.000608	CcSEcCtD
Zalcitabine—Dysgeusia—Doxorubicin—thyroid cancer	0.000272	0.000607	CcSEcCtD
Zalcitabine—Malaise—Epirubicin—thyroid cancer	0.000271	0.000604	CcSEcCtD
Zalcitabine—Nervousness—Doxorubicin—thyroid cancer	0.00027	0.000602	CcSEcCtD
Zalcitabine—Vertigo—Epirubicin—thyroid cancer	0.00027	0.000602	CcSEcCtD
Zalcitabine—Syncope—Epirubicin—thyroid cancer	0.00027	0.0006	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000269	0.0218	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000269	0.0218	CbGpPWpGaD
Zalcitabine—Leukopenia—Epirubicin—thyroid cancer	0.000269	0.000599	CcSEcCtD
Zalcitabine—Back pain—Doxorubicin—thyroid cancer	0.000269	0.000599	CcSEcCtD
Zalcitabine—Muscle spasms—Doxorubicin—thyroid cancer	0.000268	0.000596	CcSEcCtD
Zalcitabine—Palpitations—Epirubicin—thyroid cancer	0.000266	0.000592	CcSEcCtD
Zalcitabine—Loss of consciousness—Epirubicin—thyroid cancer	0.000264	0.000589	CcSEcCtD
Zalcitabine—Cough—Epirubicin—thyroid cancer	0.000262	0.000584	CcSEcCtD
Zalcitabine—Vision blurred—Doxorubicin—thyroid cancer	0.000262	0.000584	CcSEcCtD
Zalcitabine—Convulsion—Epirubicin—thyroid cancer	0.000261	0.00058	CcSEcCtD
Zalcitabine—Hypertension—Epirubicin—thyroid cancer	0.00026	0.000578	CcSEcCtD
Zalcitabine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000258	0.000575	CcSEcCtD
Zalcitabine—Anaemia—Doxorubicin—thyroid cancer	0.000257	0.000573	CcSEcCtD
Zalcitabine—Arthralgia—Epirubicin—thyroid cancer	0.000256	0.00057	CcSEcCtD
Zalcitabine—Myalgia—Epirubicin—thyroid cancer	0.000256	0.00057	CcSEcCtD
Zalcitabine—Agitation—Doxorubicin—thyroid cancer	0.000256	0.000569	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000256	0.0207	CbGpPWpGaD
Zalcitabine—Anxiety—Epirubicin—thyroid cancer	0.000255	0.000568	CcSEcCtD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000255	0.0206	CbGpPWpGaD
Zalcitabine—Discomfort—Epirubicin—thyroid cancer	0.000253	0.000563	CcSEcCtD
Zalcitabine—Malaise—Doxorubicin—thyroid cancer	0.000251	0.000559	CcSEcCtD
Zalcitabine—Dry mouth—Epirubicin—thyroid cancer	0.00025	0.000558	CcSEcCtD
Zalcitabine—Vertigo—Doxorubicin—thyroid cancer	0.00025	0.000557	CcSEcCtD
Zalcitabine—Syncope—Doxorubicin—thyroid cancer	0.00025	0.000556	CcSEcCtD
Zalcitabine—Leukopenia—Doxorubicin—thyroid cancer	0.000249	0.000555	CcSEcCtD
Zalcitabine—Confusional state—Epirubicin—thyroid cancer	0.000247	0.000551	CcSEcCtD
Zalcitabine—Palpitations—Doxorubicin—thyroid cancer	0.000246	0.000548	CcSEcCtD
Zalcitabine—Oedema—Epirubicin—thyroid cancer	0.000245	0.000546	CcSEcCtD
Zalcitabine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000245	0.000545	CcSEcCtD
Zalcitabine—Infection—Epirubicin—thyroid cancer	0.000244	0.000543	CcSEcCtD
Zalcitabine—Cough—Doxorubicin—thyroid cancer	0.000243	0.000541	CcSEcCtD
Zalcitabine—Shock—Epirubicin—thyroid cancer	0.000241	0.000538	CcSEcCtD
Zalcitabine—Convulsion—Doxorubicin—thyroid cancer	0.000241	0.000537	CcSEcCtD
Zalcitabine—Thrombocytopenia—Epirubicin—thyroid cancer	0.00024	0.000535	CcSEcCtD
Zalcitabine—Hypertension—Doxorubicin—thyroid cancer	0.00024	0.000535	CcSEcCtD
Zalcitabine—Tachycardia—Epirubicin—thyroid cancer	0.00024	0.000533	CcSEcCtD
Zalcitabine—Skin disorder—Epirubicin—thyroid cancer	0.000238	0.000531	CcSEcCtD
Zalcitabine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000237	0.000528	CcSEcCtD
Zalcitabine—Myalgia—Doxorubicin—thyroid cancer	0.000237	0.000527	CcSEcCtD
Zalcitabine—Arthralgia—Doxorubicin—thyroid cancer	0.000237	0.000527	CcSEcCtD
Zalcitabine—Anxiety—Doxorubicin—thyroid cancer	0.000236	0.000526	CcSEcCtD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000234	0.0189	CbGpPWpGaD
Zalcitabine—Discomfort—Doxorubicin—thyroid cancer	0.000234	0.000521	CcSEcCtD
Zalcitabine—Anorexia—Epirubicin—thyroid cancer	0.000234	0.000521	CcSEcCtD
Zalcitabine—Dry mouth—Doxorubicin—thyroid cancer	0.000232	0.000516	CcSEcCtD
Zalcitabine—Confusional state—Doxorubicin—thyroid cancer	0.000229	0.00051	CcSEcCtD
Zalcitabine—Oedema—Doxorubicin—thyroid cancer	0.000227	0.000506	CcSEcCtD
Zalcitabine—Infection—Doxorubicin—thyroid cancer	0.000226	0.000502	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000224	0.000498	CcSEcCtD
Zalcitabine—Shock—Doxorubicin—thyroid cancer	0.000223	0.000497	CcSEcCtD
Zalcitabine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000222	0.000495	CcSEcCtD
Zalcitabine—Insomnia—Epirubicin—thyroid cancer	0.000222	0.000494	CcSEcCtD
Zalcitabine—Tachycardia—Doxorubicin—thyroid cancer	0.000222	0.000493	CcSEcCtD
Zalcitabine—Skin disorder—Doxorubicin—thyroid cancer	0.000221	0.000491	CcSEcCtD
Zalcitabine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00022	0.000489	CcSEcCtD
Zalcitabine—Dyspnoea—Epirubicin—thyroid cancer	0.000219	0.000487	CcSEcCtD
Zalcitabine—Somnolence—Epirubicin—thyroid cancer	0.000218	0.000486	CcSEcCtD
Zalcitabine—Anorexia—Doxorubicin—thyroid cancer	0.000216	0.000482	CcSEcCtD
Zalcitabine—Dyspepsia—Epirubicin—thyroid cancer	0.000216	0.000481	CcSEcCtD
Zalcitabine—Decreased appetite—Epirubicin—thyroid cancer	0.000213	0.000475	CcSEcCtD
Zalcitabine—Fatigue—Epirubicin—thyroid cancer	0.000212	0.000471	CcSEcCtD
Zalcitabine—Pain—Epirubicin—thyroid cancer	0.00021	0.000467	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000207	0.000461	CcSEcCtD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000207	0.0167	CbGpPWpGaD
Zalcitabine—Insomnia—Doxorubicin—thyroid cancer	0.000205	0.000457	CcSEcCtD
Zalcitabine—Dyspnoea—Doxorubicin—thyroid cancer	0.000202	0.000451	CcSEcCtD
Zalcitabine—Feeling abnormal—Epirubicin—thyroid cancer	0.000202	0.00045	CcSEcCtD
Zalcitabine—Somnolence—Doxorubicin—thyroid cancer	0.000202	0.00045	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000202	0.0163	CbGpPWpGaD
Zalcitabine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000201	0.000447	CcSEcCtD
Zalcitabine—Dyspepsia—Doxorubicin—thyroid cancer	0.0002	0.000445	CcSEcCtD
Zalcitabine—Decreased appetite—Doxorubicin—thyroid cancer	0.000197	0.00044	CcSEcCtD
Zalcitabine—Fatigue—Doxorubicin—thyroid cancer	0.000196	0.000436	CcSEcCtD
Zalcitabine—Urticaria—Epirubicin—thyroid cancer	0.000195	0.000434	CcSEcCtD
Zalcitabine—Pain—Doxorubicin—thyroid cancer	0.000194	0.000432	CcSEcCtD
Zalcitabine—Body temperature increased—Epirubicin—thyroid cancer	0.000194	0.000432	CcSEcCtD
Zalcitabine—Abdominal pain—Epirubicin—thyroid cancer	0.000194	0.000432	CcSEcCtD
Zalcitabine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000187	0.000417	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000187	0.0151	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000187	0.0151	CbGpPWpGaD
Zalcitabine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000186	0.000413	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—CHST14—thyroid cancer	0.000185	0.015	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000181	0.0146	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Epirubicin—thyroid cancer	0.000181	0.000403	CcSEcCtD
Zalcitabine—Urticaria—Doxorubicin—thyroid cancer	0.00018	0.000402	CcSEcCtD
Zalcitabine—Body temperature increased—Doxorubicin—thyroid cancer	0.00018	0.0004	CcSEcCtD
Zalcitabine—Abdominal pain—Doxorubicin—thyroid cancer	0.00018	0.0004	CcSEcCtD
Zalcitabine—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000178	0.0144	CbGpPWpGaD
Zalcitabine—Asthenia—Epirubicin—thyroid cancer	0.000176	0.000392	CcSEcCtD
Zalcitabine—Pruritus—Epirubicin—thyroid cancer	0.000174	0.000387	CcSEcCtD
Zalcitabine—Diarrhoea—Epirubicin—thyroid cancer	0.000168	0.000374	CcSEcCtD
Zalcitabine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000167	0.000373	CcSEcCtD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000164	0.0133	CbGpPWpGaD
Zalcitabine—Asthenia—Doxorubicin—thyroid cancer	0.000163	0.000363	CcSEcCtD
Zalcitabine—Dizziness—Epirubicin—thyroid cancer	0.000162	0.000361	CcSEcCtD
Zalcitabine—Pruritus—Doxorubicin—thyroid cancer	0.000161	0.000358	CcSEcCtD
Zalcitabine—Vomiting—Epirubicin—thyroid cancer	0.000156	0.000347	CcSEcCtD
Zalcitabine—Diarrhoea—Doxorubicin—thyroid cancer	0.000155	0.000346	CcSEcCtD
Zalcitabine—Rash—Epirubicin—thyroid cancer	0.000155	0.000345	CcSEcCtD
Zalcitabine—Dermatitis—Epirubicin—thyroid cancer	0.000155	0.000344	CcSEcCtD
Zalcitabine—Headache—Epirubicin—thyroid cancer	0.000154	0.000342	CcSEcCtD
Zalcitabine—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000151	0.0123	CbGpPWpGaD
Zalcitabine—Dizziness—Doxorubicin—thyroid cancer	0.00015	0.000334	CcSEcCtD
Zalcitabine—Vomiting—Doxorubicin—thyroid cancer	0.000144	0.000321	CcSEcCtD
Zalcitabine—Rash—Doxorubicin—thyroid cancer	0.000143	0.000319	CcSEcCtD
Zalcitabine—Dermatitis—Doxorubicin—thyroid cancer	0.000143	0.000319	CcSEcCtD
Zalcitabine—Headache—Doxorubicin—thyroid cancer	0.000142	0.000317	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00014	0.0113	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000137	0.0111	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000137	0.0111	CbGpPWpGaD
Zalcitabine—CYP3A43—Biological oxidations—RXRA—thyroid cancer	0.000135	0.011	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000135	0.0109	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000134	0.0108	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000127	0.0102	CbGpPWpGaD
Zalcitabine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000107	0.00864	CbGpPWpGaD
Zalcitabine—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000107	0.00864	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000106	0.00861	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000106	0.00861	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000106	0.00861	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000103	0.00835	CbGpPWpGaD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000103	0.00831	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000102	0.00829	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—MINPP1—thyroid cancer	0.000101	0.00817	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—MINPP1—thyroid cancer	9.95e-05	0.00805	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	9.49e-05	0.00768	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CP—thyroid cancer	9.49e-05	0.00768	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—TPR—thyroid cancer	9.49e-05	0.00768	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	9.41e-05	0.00762	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.33e-05	0.00755	CbGpPWpGaD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	9.15e-05	0.00741	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.61e-05	0.00697	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—NDUFA13—thyroid cancer	8.59e-05	0.00695	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NDUFA13—thyroid cancer	8.46e-05	0.00685	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CHST14—thyroid cancer	8.07e-05	0.00654	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	7.96e-05	0.00644	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CHST14—thyroid cancer	7.95e-05	0.00644	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	7.46e-05	0.00604	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	7.46e-05	0.00604	CbGpPWpGaD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	7.42e-05	0.00601	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.1e-05	0.00575	CbGpPWpGaD
Zalcitabine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	7.04e-05	0.0057	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	7.01e-05	0.00567	CbGpPWpGaD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	6.51e-05	0.00527	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—HPGD—thyroid cancer	6.51e-05	0.00527	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	6.45e-05	0.00522	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	6.42e-05	0.00519	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—HPGD—thyroid cancer	6.41e-05	0.00519	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	6.21e-05	0.00502	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.97e-05	0.00483	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	5.59e-05	0.00452	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—RXRA—thyroid cancer	5.45e-05	0.00441	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—TPR—thyroid cancer	5.41e-05	0.00437	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CP—thyroid cancer	5.41e-05	0.00437	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.32e-05	0.0043	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.28e-05	0.00427	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.23e-05	0.00423	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.26e-05	0.00344	CbGpPWpGaD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	4.23e-05	0.00343	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.05e-05	0.00327	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—MINPP1—thyroid cancer	4.01e-05	0.00324	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—RXRA—thyroid cancer	3.94e-05	0.00319	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	3.79e-05	0.00307	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	3.79e-05	0.00307	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—TPR—thyroid cancer	3.74e-05	0.00303	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.73e-05	0.00302	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	3.71e-05	0.003	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—TPR—thyroid cancer	3.68e-05	0.00298	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PRKAR1A—thyroid cancer	3.68e-05	0.00298	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PRKAR1A—thyroid cancer	3.62e-05	0.00293	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.45e-05	0.00279	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NDUFA13—thyroid cancer	3.41e-05	0.00276	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.4e-05	0.00275	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CHST14—thyroid cancer	3.2e-05	0.00259	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.95e-05	0.00239	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—MINPP1—thyroid cancer	2.9e-05	0.00234	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.84e-05	0.0023	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	2.8e-05	0.00227	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—SLC5A5—thyroid cancer	2.8e-05	0.00226	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—RXRA—thyroid cancer	2.78e-05	0.00225	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—SLC5A5—thyroid cancer	2.76e-05	0.00223	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—HPGD—thyroid cancer	2.58e-05	0.00209	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NDUFA13—thyroid cancer	2.46e-05	0.00199	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.38e-05	0.00193	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—RXRA—thyroid cancer	2.35e-05	0.0019	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—RXRA—thyroid cancer	2.32e-05	0.00187	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CHST14—thyroid cancer	2.32e-05	0.00187	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—MINPP1—thyroid cancer	2.06e-05	0.00167	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—MINPP1—thyroid cancer	2.04e-05	0.00165	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—HPGD—thyroid cancer	1.87e-05	0.00151	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.83e-05	0.00148	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	1.75e-05	0.00142	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NDUFA13—thyroid cancer	1.74e-05	0.0014	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CHST14—thyroid cancer	1.65e-05	0.00133	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CHST14—thyroid cancer	1.63e-05	0.00132	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PPARG—thyroid cancer	1.48e-05	0.0012	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—TPR—thyroid cancer	1.48e-05	0.0012	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PPARG—thyroid cancer	1.46e-05	0.00118	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	1.46e-05	0.00118	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.35e-05	0.00109	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—HPGD—thyroid cancer	1.33e-05	0.00107	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—HPGD—thyroid cancer	1.32e-05	0.00106	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTGS2—thyroid cancer	1.17e-05	0.000945	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTGS2—thyroid cancer	1.15e-05	0.000931	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.14e-05	0.000927	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—SLC5A5—thyroid cancer	1.11e-05	0.000898	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CHST14—thyroid cancer	1.08e-05	0.000871	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—TPR—thyroid cancer	1.07e-05	0.000868	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.07e-05	0.000864	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	1.05e-05	0.000853	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTEN—thyroid cancer	1.02e-05	0.000824	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTEN—thyroid cancer	1e-05	0.000812	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—RXRA—thyroid cancer	9.33e-06	0.000755	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—HPGD—thyroid cancer	8.68e-06	0.000702	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—SLC5A5—thyroid cancer	8.02e-06	0.000649	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—TPR—thyroid cancer	7.62e-06	0.000617	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—TPR—thyroid cancer	7.56e-06	0.000612	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	7.5e-06	0.000607	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	7.43e-06	0.000602	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—RXRA—thyroid cancer	6.74e-06	0.000546	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.74e-06	0.000545	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PPARG—thyroid cancer	5.89e-06	0.000477	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKT1—thyroid cancer	5.87e-06	0.000475	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKT1—thyroid cancer	5.78e-06	0.000468	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	5.71e-06	0.000462	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—SLC5A5—thyroid cancer	5.66e-06	0.000458	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.3e-06	0.000429	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—TPR—thyroid cancer	4.98e-06	0.000403	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.9e-06	0.000397	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—RXRA—thyroid cancer	4.79e-06	0.000388	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—RXRA—thyroid cancer	4.75e-06	0.000385	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTGS2—thyroid cancer	4.63e-06	0.000375	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.62e-06	0.000374	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PPARG—thyroid cancer	4.26e-06	0.000345	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTEN—thyroid cancer	4.04e-06	0.000327	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.73e-06	0.000302	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTGS2—thyroid cancer	3.35e-06	0.000271	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—RXRA—thyroid cancer	3.13e-06	0.000254	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PPARG—thyroid cancer	3.03e-06	0.000245	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PPARG—thyroid cancer	3e-06	0.000243	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTEN—thyroid cancer	2.92e-06	0.000236	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.38e-06	0.000193	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTGS2—thyroid cancer	2.36e-06	0.000191	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKT1—thyroid cancer	2.33e-06	0.000188	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTEN—thyroid cancer	2.08e-06	0.000168	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTEN—thyroid cancer	2.06e-06	0.000167	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PPARG—thyroid cancer	1.98e-06	0.00016	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKT1—thyroid cancer	1.68e-06	0.000136	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.56e-06	0.000126	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTEN—thyroid cancer	1.36e-06	0.00011	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKT1—thyroid cancer	1.2e-06	9.69e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKT1—thyroid cancer	1.19e-06	9.6e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKT1—thyroid cancer	7.82e-07	6.33e-05	CbGpPWpGaD
